Genprex (GNPX) Competitors $0.27 -0.07 (-21.05%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.29 +0.02 (+7.04%) As of 03/28/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GNPX vs. APRE, CSCI, TRIB, BCDA, SNSE, MBRX, BLRX, TLPH, PMCB, and QNTMShould you be buying Genprex stock or one of its competitors? The main competitors of Genprex include Aprea Therapeutics (APRE), COSCIENS Biopharma (CSCI), Trinity Biotech (TRIB), BioCardia (BCDA), Sensei Biotherapeutics (SNSE), Moleculin Biotech (MBRX), BioLineRx (BLRX), Talphera (TLPH), PharmaCyte Biotech (PMCB), and Quantum Biopharma (QNTM). These companies are all part of the "pharmaceutical products" industry. Genprex vs. Aprea Therapeutics COSCIENS Biopharma Trinity Biotech BioCardia Sensei Biotherapeutics Moleculin Biotech BioLineRx Talphera PharmaCyte Biotech Quantum Biopharma Genprex (NASDAQ:GNPX) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Which has preferable earnings & valuation, GNPX or APRE? Aprea Therapeutics has higher revenue and earnings than Genprex. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenprexN/AN/A-$30.86MN/AN/AAprea Therapeutics$580K19.79-$14.29M-$2.38-0.88 Do insiders & institutionals have more ownership in GNPX or APRE? 14.1% of Genprex shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 8.5% of Genprex shares are held by insiders. Comparatively, 12.8% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in GNPX or APRE? Genprex received 143 more outperform votes than Aprea Therapeutics when rated by MarketBeat users. Likewise, 65.25% of users gave Genprex an outperform vote while only 57.14% of users gave Aprea Therapeutics an outperform vote. CompanyUnderperformOutperformGenprexOutperform Votes19965.25% Underperform Votes10634.75% Aprea TherapeuticsOutperform Votes5657.14% Underperform Votes4242.86% Does the media favor GNPX or APRE? In the previous week, Aprea Therapeutics had 11 more articles in the media than Genprex. MarketBeat recorded 17 mentions for Aprea Therapeutics and 6 mentions for Genprex. Aprea Therapeutics' average media sentiment score of 0.55 beat Genprex's score of 0.35 indicating that Aprea Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genprex 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Aprea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do analysts recommend GNPX or APRE? Genprex presently has a consensus price target of $10.00, indicating a potential upside of 3,603.70%. Aprea Therapeutics has a consensus price target of $15.50, indicating a potential upside of 641.63%. Given Genprex's higher possible upside, equities analysts clearly believe Genprex is more favorable than Aprea Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aprea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, GNPX or APRE? Genprex has a beta of -0.16, suggesting that its share price is 116% less volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Is GNPX or APRE more profitable? Genprex has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,029.50%. Aprea Therapeutics' return on equity of -57.86% beat Genprex's return on equity.Company Net Margins Return on Equity Return on Assets GenprexN/A -409.48% -269.17% Aprea Therapeutics -1,029.50%-57.86%-47.94% SummaryAprea Therapeutics beats Genprex on 10 of the 14 factors compared between the two stocks. Remove Ads Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGenprexPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.31M$6.90B$5.63B$7.84BDividend YieldN/A2.77%5.33%4.01%P/E RatioN/A7.2623.6018.74Price / SalesN/A218.62388.2390.77Price / CashN/A65.6738.1734.64Price / Book0.056.386.894.23Net Income-$30.86M$142.34M$3.20B$247.47M7 Day Performance-24.50%-5.15%-3.06%-2.29%1 Month Performance-28.38%-7.55%1.52%-5.81%1 Year Performance-90.94%-11.06%9.37%-0.96% Genprex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGenprex4.3971 of 5 stars$0.27-21.1%$10.00+3,603.7%-90.9%$2.31MN/A0.0020Short Interest ↓News CoverageAPREAprea Therapeutics2.8588 of 5 stars$2.26-5.4%$15.50+585.8%-68.8%$12.28M$580,000.00-0.807Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageGap UpCSCICOSCIENS BiopharmaN/A$3.22+0.6%N/AN/A$12.16M$7.60M-0.2720High Trading VolumeTRIBTrinity Biotech1.4765 of 5 stars$0.66-6.1%N/A-67.5%$12.00M$59.13M-0.29480Upcoming EarningsAnalyst ForecastBCDABioCardia2.8821 of 5 stars$2.60-2.3%$25.00+861.5%-54.1%$11.92M$71,000.00-0.6240Earnings ReportShort Interest ↑SNSESensei Biotherapeutics4.5393 of 5 stars$0.46-5.2%$4.33+832.7%-51.6%$11.69MN/A-0.3940Earnings ReportUpcoming EarningsAnalyst ForecastShort Interest ↓News CoverageGap UpMBRXMoleculin Biotech2.8977 of 5 stars$1.06-2.8%$18.67+1,661.0%-82.4%$11.51MN/A0.0020Analyst UpgradeShort Interest ↓Analyst RevisionNews CoverageBLRXBioLineRx2.6009 of 5 stars$3.42-4.5%$360.00+10,426.3%-93.2%$11.39M$21.99M-0.3940Upcoming EarningsTLPHTalphera2.1037 of 5 stars$0.64+0.7%$4.33+578.0%-43.1%$10.88M$281,000.00-0.9319Short Interest ↑News CoveragePMCBPharmaCyte Biotech1.3611 of 5 stars$1.57-0.6%N/A-44.3%$10.78MN/A2.964Short Interest ↑Positive NewsQNTMQuantum BiopharmaN/A$5.55-1.9%N/AN/A$10.65MN/A-0.36N/AEarnings ReportUpcoming EarningsNews CoverageGap Up Remove Ads Related Companies and Tools Related Companies APRE Competitors CSCI Competitors TRIB Competitors BCDA Competitors SNSE Competitors MBRX Competitors BLRX Competitors TLPH Competitors PMCB Competitors QNTM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNPX) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GNPX Stock Free GNPX Stock Alerts